Takeda Pharmaceutical Company Limited (TAK) — AI 주식 분석

Name: TAK 재무 데이터
Creator: Stock Expert AI
License: https://www.stockexpertai.com/terms

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

TAK는 Takeda Pharmaceutical Company Limited를 나타내며, 현재 주가는 $17.05입니다. 이 주식은 Stock Expert AI의 정량 평가 모델에서 56/100, 중간 등급입니다.

Takeda 제약 Company Limited is a global 제약 company focused on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Founded in 1781, Takeda has a long history of developing and marketing 혁신적인 medicines.

주요 정보: 가격: $17.05 일일 변동: -0.58% 시가총액: $54.2B 애널리스트 목표가: $20.68 목표가 상승여력: +21.3% AI 점수: 56/100 거래소: NASDAQ

기업 개요

요약:

Takeda 제약 Company Limited (TAK) is a global 제약 leader specializing in gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. With a rich heritage dating back to 1781, Takeda 레버리지s 전략적 collaborations and a diverse product portfolio to address unmet medical needs across international markets, generating a 3.49% 배당수익률.

TAK는 무엇을 하는 회사인가요?

Founded in 1781 and headquartered in Tokyo, Japan, Takeda 제약 Company Limited has evolved from a traditional medicine vendor to a global bio제약 leader. The company engages in the research, development, manufacture, marketing, and out-licensing of 제약 products across Japan, the United States, Europe, Canada, 라틴 아메리카, Russia, and other parts of Asia. Takeda's core therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its diverse product portfolio features well-known brands such as Entyvio for inflammatory bowel disease, Gattex/Revestive for short bowel syndrome, and Velcade for multiple myeloma. Through 전략적 collaborations and licensing agreements with entities like Neurocrine Biosciences, Arrowhead 제약, and MD Anderson Cancer Center, Takeda continues to expand its 파이프라인 and address unmet medical needs worldwide. With approximately 49,281 임직원, Takeda is committed to delivering 혁신적인 treatments and improving patient outcomes globally.

TAK의 투자 테제는 무엇인가요?

Takeda 제약 Company Limited presents a compelling investment case driven by its focus on specialty therapeutic areas and global reach. With a 시가총액 of $56.14 billion and a 배당수익률 of 3.49%, Takeda offers a blend of value and income. Growth catalysts include the continued expansion of key products like Entyvio and Takhzyro, as well as potential breakthroughs from its extensive 연구개발(R&D) 파이프라인. The company's 순이익률 of 2.5% and 매출총이익률 of 59.5% indicate solid 수익성, while a low 베타 of 0.10 suggests relatively low 변동성. However, 투자자 should be aware of risks related to patent expirations and competition from generic drugs. Takeda's 전략적 collaborations and licensing agreements are expected to fuel 장기 growth and 혁신.

TAK는 어떤 산업에서 운영되고 있나요?

Takeda 제약 Company Limited operates within the highly competitive global 제약 industry, which is characterized by intense 연구개발(R&D), stringent 규제 requirements, and patent protection. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in 바이오테크. Takeda competes with major 제약 companies, including ALC, BDX, and CAH, as well as smaller 바이오테크 firms. The company's focus on specialty therapeutic areas and 전략적 collaborations positions it to capitalize on emerging market trends and maintain a competitive edge.

Drug Manufacturers - Specialty & Generic

헬스케어

TAK의 성장 기회는 무엇인가요?

Expansion of Gastroenterology Portfolio: Takeda can 레버리지 the success of Entyvio to further expand its gastroenterology portfolio. The 글로벌 시장 for inflammatory bowel disease (IBD) therapeutics is projected to reach $22.5 billion by 2028, offering 상당한 성장 잠재력. Takeda can invest in new formulations, indications, and geographic markets to capture a larger share of this growing market. Timeline: 진행 중인.
Development of Rare Disease Therapies: Takeda's focus on rare diseases provides a unique growth opportunity. The rare disease therapeutics market is expected to reach $259.9 billion by 2030. By investing in 연구개발(R&D) of 혁신적인 therapies for rare diseases, Takeda can address unmet medical needs and generate substantial 매출. Timeline: 진행 중인.
Advancement of Oncology 파이프라인: Takeda can drive growth by advancing its oncology 파이프라인 and launching new cancer therapies. The global oncology market is projected to reach $286.6 billion by 2030. Takeda's 전략적 collaborations and licensing agreements in oncology can accelerate the development and commercialization of novel cancer treatments. Timeline: 진행 중인.
Growth in Plasma-Derived Therapies: Takeda can capitalize on the increasing demand for plasma-derived therapies. The global plasma-derived therapies market is expected to reach $46.8 billion by 2027. Takeda can expand its plasma collection network and manufacturing capacity to meet the growing demand for these life-saving therapies. Timeline: 진행 중인.
전략적 파트너십 and 인수: Takeda can pursue 전략적 파트너십 and 인수 to expand its product portfolio and geographic reach. By acquiring companies with complementary products and technologies, Takeda can accelerate its growth and strengthen its 경쟁적 입지. The company's existing collaborations with Neurocrine Biosciences and other firms demonstrate its commitment to this strategy. Timeline: 진행 중인.

시가총액 of $56.14 billion reflects Takeda's 상당한 presence in the global 제약 market.
주가수익비율(P/E) of 79.35 indicates 투자자 expectations for future 실적 성장.
배당수익률 of 3.49% provides an attractive income stream for 투자자.
매출총이익률 of 59.5% demonstrates efficient cost 경영진 and strong 가격 결정력.
베타 of 0.10 suggests lower 변동성 compared to the broader market, making it a potentially stable investment.

TAK는 어떤 제품과 서비스를 제공하나요?

Researches and develops 제약 products.
Manufactures 제약 products.
Markets and sells 제약 products globally.
Out-licenses 제약 products to other companies.
Focuses on therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience.
Collaborates with other companies and research institutions to develop new therapies.

TAK는 어떻게 수익을 창출하나요?

Develops and commercializes prescription drugs.
Generates 매출 through sales of its 제약 products.
Out-licenses certain products to other companies for royalties.
Invests heavily in 연구개발(R&D) to discover new drugs.

Patients who need prescription medications.
Hospitals and clinics that administer medications.
Pharmacies that dispense medications.
Healthcare providers who prescribe medications.

Strong 브랜드 인지도 and reputation in the 제약 industry.
Extensive patent portfolio protecting its key products.
Global distribution network and established relationships with healthcare providers.
Expertise in developing and commercializing specialty 제약 products.

TAK 주가를 상승시킬 수 있는 요인은 무엇인가요?

진행 중인: Continued growth of key products such as Entyvio and Takhzyro driving 매출 성장.
예정된: Potential FDA 승인 of new drug candidates in Takeda's 파이프라인.
진행 중인: 전략적 collaborations and licensing agreements expanding Takeda's product portfolio.
진행 중인: Cost-cutting initiatives and operational efficiencies improving 수익성.

TAK의 주요 리스크는 무엇인가요?

Potential: Patent expirations on key products leading to generic competition.
진행 중인: 규제 challenges and pricing pressures in the 제약 industry.
Potential: Product liability lawsuits and recalls impacting reputation and 재무 성과.
진행 중인: Currency fluctuations affecting the value of Takeda's ADRs.

TAK의 핵심 강점은 무엇인가요?

Strong presence in key therapeutic areas.
Global reach and distribution network.
Robust 연구개발(R&D) 파이프라인.
전략적 collaborations and licensing agreements.

TAK의 약점은 무엇인가요?

Reliance on a limited number of key products.
Exposure to patent expirations and generic competition.
High 부채 levels following the Shire 인수.
순이익률 of 2.5% is relatively low compared to peers.

TAK에게 어떤 기회가 있나요?

Expansion into 신흥 시장.
Development of new therapies for unmet medical needs.
인수 of complementary businesses and technologies.
Growth in the rare disease and oncology markets.

TAK는 어떤 위협에 직면하고 있나요?

Increasing competition from generic drug manufacturers.
Stringent 규제 requirements and pricing pressures.
Product liability lawsuits and recalls.
경기침체s and healthcare reforms.

TAK의 경쟁사는 누구인가요?

Agilent Technologies Inc. — Focuses on life sciences, diagnostics, and applied chemical markets. — (A)
Alcon Inc. — Specializes in eye care products. — (ALC)
Becton, Dickinson and Company — Provides 의료기기 and diagnostic products. — (BDX)
Cardinal Health Inc. — Distributes 제약 and provides healthcare services. — (CAH)
Edwards Lifesciences Corporation — Focuses on heart valve technologies and critical care monitoring. — (EW)

목표 주가

Analyst Consensus Target: $20.68
Current price: $18.29
Implied Upside: +13.1%

회사 프로필

CEO: Christophe Weber
Headquarters: Tokyo, JP
Employees: 49,281
Founded: 2010

AI 인사이트

Takeda 제약 Company Limited researches, develops, manufactures, and markets 제약 products. Their products focus on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience.

질문 및 답변

What does Takeda 제약 Company Limited do?

Takeda 제약 Company Limited is a global bio제약 company focused on developing and commercializing 혁신적인 medicines in gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company researches, develops, manufactures, and markets 제약 products worldwide. Takeda's diverse product portfolio includes well-known brands like Entyvio for inflammatory bowel disease and Velcade for multiple myeloma. Through 전략적 collaborations and licensing agreements, Takeda aims to address unmet medical needs and improve patient outcomes globally.

What do analysts say about TAK stock?

Analyst 컨센서스 on Takeda 제약 Company Limited (TAK) is generally positive, citing the company's strong presence in key therapeutic areas and its robust 파이프라인 of new drug candidates. Key 밸류에이션 metrics include a 주가수익비율(P/E) of 79.35 and a 배당수익률 of 3.49%. Growth considerations include the continued expansion of key products and potential breakthroughs from its 연구개발(R&D) efforts. However, analysts also note risks related to patent expirations and competition from generic drugs. This is a neutral summary of analyst sentiment and does not constitute investment advice.

What are the main risks for TAK?

Takeda 제약 Company Limited faces several risks, including patent expirations on key products, which could lead to generic competition and reduced 매출. The company also faces 규제 challenges and pricing pressures in the 제약 industry, which could impact 수익성. Product liability lawsuits and recalls could damage Takeda's reputation and 재무 성과. Additionally, currency fluctuations could affect the value of Takeda's ADRs, particularly given its 상당한 international operations. These risks are inherent in the 제약 industry and require careful monitoring.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.